The Science Behind Eye & Vision Supplements

Therapeutic dose: 10 mg/day

See ranked Lutein products→

• AREDS2 (2013, JAMA, 4,203 participants) found lutein + zeaxanthin was a safe and effective replacement for beta-carotene in the AREDS formulation for reducing advanced AMD progression.PubMed ↗
• 2023 meta-analysis of 20 RCTs confirmed lutein supplementation significantly increases macular pigment optical density (MPOD), the primary biomarker for macular protection.PubMed ↗
• Lutein accumulates in the macula periphery (vs zeaxanthin centrally). Together they form the macular pigment that filters blue light and provides antioxidant protection to photoreceptors.
• 10 mg/day is the dose used in AREDS2 and most positive RCTs. Higher doses have not shown additional benefit.

Therapeutic dose: 2 mg/day

See ranked Zeaxanthin products→

• AREDS2 used 2 mg zeaxanthin alongside 10 mg lutein. The combination significantly reduced risk of progression to advanced AMD in participants with low dietary intake of these carotenoids.PubMed ↗
• Zeaxanthin concentrates in the central macula (fovea) where visual acuity is highest. Lutein dominates the peripheral macula. Both are needed for complete macular pigment coverage.
• AREDS2 10-year follow-up confirmed sustained benefit of lutein/zeaxanthin and established it as the preferred formulation over the original beta-carotene-containing AREDS formula.PubMed ↗

Therapeutic dose: 25–80 mg/day (AREDS2 used 25 mg oxide equivalent)

See ranked Zinc products→

• Original AREDS trial (2001, 3,640 participants) found zinc 80 mg/day + antioxidants reduced risk of advanced AMD by 25%. Zinc alone reduced risk by 21%.PubMed ↗
• AREDS2 reduced zinc from 80 mg to 25 mg with no loss of efficacy, while reducing GI side effects and copper depletion risk.
• Zinc is essential for retinal function — retinal pigment epithelium has one of the highest zinc concentrations in the body. Deficiency impairs visual adaptation and retinal health.

Therapeutic dose: 4–12 mg/day

• 2012 RCT (49 participants) found 6 mg astaxanthin daily for 4 weeks significantly improved accommodation amplitude and reduced eye fatigue in VDT workers.PubMed ↗
• Crosses the blood-retina barrier (unlike most carotenoids) and concentrates in the retina. Provides antioxidant protection complementary to lutein/zeaxanthin.
• Most studies focus on asthenopia (eye strain) rather than age-related disease. Evidence for AMD prevention is theoretical — no long-term RCTs.

Therapeutic dose: 700–900 mcg RAE/day (RDA)

See ranked Vitamin A (Retinol) products→

• Vitamin A is required for rhodopsin synthesis — the light-sensitive pigment in rod cells. Deficiency causes night blindness (nyctalopia), the earliest symptom of vitamin A deficiency.
• Supplementation reverses night blindness in deficient individuals. However, in vitamin A-sufficient populations (most Western adults), additional supplementation has no proven visual benefit.
• Caution: excess retinol (>3,000 mcg/day) is teratogenic and hepatotoxic. Beta-carotene was removed from AREDS2 due to lung cancer risk in smokers. Retinol supplementation requires care.

Therapeutic dose: 250–500 mg DHA/day

See ranked Omega-3 (DHA) products→

• DHA comprises ~60% of the fatty acids in retinal photoreceptor outer segments. Observational studies consistently link higher omega-3 intake with lower AMD risk.
• However, AREDS2 found no statistically significant benefit from adding DHA/EPA (1,000 mg/350 mg) to the lutein/zeaxanthin + zinc formulation.PubMed ↗
• The disconnect between observational and trial data suggests omega-3 may be important for retinal development and maintenance, but supplementation on top of an adequate diet may not add measurable benefit.

Therapeutic dose: 20–30 mg/day

See ranked Saffron (Crocus sativus) products→

• 2010 RCT (25 early AMD patients) found 20 mg/day saffron for 3 months significantly improved macular function (focal ERG) compared to placebo.PubMed ↗
• 2016 follow-up study found effects were sustained over 14 months of supplementation.PubMed ↗
• Active compounds (crocin, crocetin) have anti-apoptotic and antioxidant effects on retinal cells. Promising but all studies are from the same research group — needs independent replication.

Therapeutic dose: 250–500 mg/day

See ranked Vitamin C (for Vision) products→

• Included in the original AREDS formula (500 mg) as an antioxidant. The formula worked as a combination — vitamin C's individual contribution to the eye benefit cannot be isolated.
• Observational studies link higher vitamin C intake with lower cataract risk, but no RCTs have tested vitamin C alone for AMD or cataract prevention.

Therapeutic dose: 400 IU/day (as part of AREDS formula)

See ranked Vitamin E (for Vision) products→

• Included in original AREDS (400 IU) as an antioxidant. Like vitamin C, its individual contribution is inseparable from the combination formula.
• High-dose vitamin E alone (400 IU/day) has not been shown to prevent AMD or cataracts in any standalone RCT. Some meta-analyses raised concerns about all-cause mortality at high doses.